Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Cell Death and Differentiation

Volumn 20, Issue 7, 2013, Pages 898-909

  Hanel, W ^a   Marchenko, N ^a   Xu, S ^a   Xiaofeng Yu, S ^a,c   Weng, W ^b   Moll, U ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Ingenious Targeting Inc   (United States)

^c Applied Stem Cell Inc   (United States)

Author keywords

Gain of function; HUPKI; LSK; MSC

Indexed keywords

PROTEIN KINASE B; PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CODON; FAMILIAL CANCER; GAIN OF FUNCTION MUTATION; GENE DELETION; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; LYMPHOMA; MESENCHYMAL STEM CELL; METASTASIS; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ADULT; ALLELES; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; HUMANS; LI-FRAUMENI SYNDROME; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84880302677     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.17     Document Type: Article

References (38)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
2. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta 2009; 1787: 414-420.
3. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
4. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788-6793.
5. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
6. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
7. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
8. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007; 9: 573-580.
9. Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010; 29: 949-956.
10. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001; 20: 320-328.
11. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor- DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
12. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
13. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
14. Bertout JA, Patel SA, Fryer BH, Durham AC, Covello KL, Olive KP et al. Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res 2009; 69: 3213-3220.
15. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150: 1-13.
16. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-538.
17. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998; 17: 1061-1068.
18. Trkova M, Foretova L, Kodet R, Hedvicakova P, Sedlacek ZA. Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. Cancer Genet Cytogenet 2003; 145: 60-64.
19. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
20. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
21. Torchia EC, Caulin C, Acin S, Terzian T, Kubick BJ, Box NF et al. Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene 2011; 31: 2680-2690.
22. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994; 145: 702-714.
23. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
24. Haines BB, Ryu CJ, Chang S, Protopopov A, Luch A, Kang YH et al. Block of T cell development in P53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations. Cancer Cell 2006; 9: 109-120.
25. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37-48.
26. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-295.
27. Yoshikawa K, Hamada J, Tada M, Kameyama T, Nakagawa K, Suzuki Y et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res 2010; 31: 401-411.
28. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138: 1083-1095.
29. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. p53 suppresses the self-renewal of adult neural stem cells. Development 2006; 133: 363-369.
30. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002; 99: 2948-2953.
31. Lee MK, Sabapathy K. The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo. J Cell Sci 2008; 121: 1899-1906.
32. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20: 246-259.
33. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012; 113: 433-439.
34. Morse HC 3rd, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002; 100: 246-258.
35. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002; 100: 238-245.
36. Cowell JK, Matsui S, Wang YD, LaDuca J, Conroy J, McQuaid D et al. Application of bacterial artificial chromosome array-based comparative genomic hybridization and spectral karyotyping to the analysis of glioblastoma multiforme. Cancer Genet Cytogenet 2004; 151: 36-51.
37. Petrenko O, Beavis A, Klaine M, Kittappa R, Godin I, Lemischka IR. The molecular characterization of the fetal stem cell marker AA4. Immunity 1999; 10: 691-700.
38. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47-54.